• Explore /
  • Poster
  • / Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath.

Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath.

Abstract Poster

Authors

null

Francois-Xaxier Mahon

Université Victor Ségalen, Bordeaux, France

Francois-Xaxier Mahon , Michele Baccarani , Michael J. Mauro , Timothy P. Hughes , Giuseppe Saglio , Michael Savona , Tomasz K. Szczudlo , Hans D. Menssen , Christopher Hunt Keir , Claudia Walasek , Andreas Hochhaus

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Leukemia, Myelodysplasia, and Transplantation

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Leukemia

Clinical Trial Registration Number

NCT01784068

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr TPS7124)

DOI

10.1200/jco.2014.32.15_suppl.tps7124

Abstract #

TPS7124

Poster Bd #

406B

Abstract Disclosures

Similar Posters

First Author: Rüdiger Hehlmann

First Author: Benjamin J. Solomon

First Author: Georg-Nikolaus Franke

First Author: Timothy P Hughes